Diversity, Equity & Inclusion Program Learning Outcomes Considerations

Based on an analysis of 2020-2021 submissions of diversity, equity, and inclusion (DEI) program learning outcome (PLOs) and feedback from curriculum developers, we developed this handout in order to facilitate the development of future impactful outcomes (K. Lybeck, J. Schomberg, K. Scott, May 2021). We hope that our advice for conceptualizing, writing, and reviewing DEI PLOs is useful to faculty. This advice will not resolve DEI problems in the curriculum, but it may help us work toward change

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevitably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensitive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT, NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.Peer reviewe

2021 Scholars At Work Conference Program

Program for the 2021 Scholars At Work Conference at Minnesota State University, Mankato on October 1, 2021

Minnesota In-Service Teacher Perspectives on Pre-Professional Education

This report gives the results of a survey given to in-service ESL teachers in Minnesota regarding the relationship between their pre-service preparation and their current practice1. The purpose of this survey was to help inform teacher educators about those areas that in-service teacher’s felt they needed more preparation in order to strengthen both pre-service preparation and continuing professional development. The purpose of this report is to share this information with other programs that might also benefit from it.Lybeck, Karen. (2009). Minnesota In-Service Teacher Perspectives on Pre-Professional Education. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/109938

How the Faculty Fellows Program Supports Faculty\u27s Scholarly Innovations and Teaching Innovations

This panel discussion will feature Dr. Aaron Budge and Dr. Karen Lybeck, who will discuss CETL\u27s Faculty Fellows program. They will also discussthe benefits for faculty who engaging in these programs and how the programcan support faculty member\u27s Professional Development Plans and Reports.Lastly, they will discuss the benefits for student success and our campuscommunity

Investigating the New Diversity, Equity, and Inclusion Program Level Outcome Requirements

The purpose of this study was to investigate the understanding and experiences that MSU-Mankato faculty had with developing the recently mandated diversity, equity, and inclusion outcomes for new and revised program proposals. Of particular interest for this study were the participants\u27 experiences writing these outcomes, their understanding of what these outcomes entail, how they planned to integrate and assess this content into their courses, and what professional development could be implemented in the future

DEI Curriculur Initiatives: Transformational Change or Mere Performance?

The purpose of this study was to investigate the understanding and experiences that MSU-Mankato faculty have had with developing the recently mandated diversity, equity, and inclusion outcomes for new and revised program proposals. These outcomes are part of the Equity 2030 initiative. The research is broken up into two sections, which will be published as separate papers. Project 1: Using critical discourse analysis, we problematize and critique both the stated goals and the implementation of this initiative. Using the lens of critical race theory (CRT), we work to unmask language that maintains Whiteness as a neutral default by asking these research questions: Will the language of DEI in institutional communication as used by administrators and faculty challenge or maintain systemic bias? Will the language of subsequent DEI proposals challenge or maintain Whiteness as uncritiqued norm? Project 2: Of particular interest for this study were the participants\u27 experiences writing these outcomes, their understanding of what these outcomes entail, how they planned to integrate this content into their courses and assess these outcomes, and what professional development they would like to see to help them integrate and assess these program outcomes in the future. We evaluated faculty member’s current ability to write, teach, and assess DEI outcomes using mixed methods research (survey and interviews). We used text analysis tools to compare faculty definitions of equity, diversity, and inclusion to the definitions provided by the Association of American Colleges & Universities as well as to Manning Marbles’ articulations of the terms corporate multiculturalism, liberal multiculturalism, and radical democratic multiculturalism. We also discussed what types of professional development faculty would be willing to invest in as well as what areas of professional development are most effective in promoting EDI outcomes, based on extant research

Teaching for Equity 2030: Integrating the First-Year Seminar

The purpose of this project is to move the discussion in international education away from coping mechanisms and assimilation strategies toward a more inclusive classroom environment. Using long-form qualitative interviews, this project analyzed current FYEX 100 and KSP 106 instructors’ methods to facilitate an inclusive classroom environment. The presentation will highlight both success and barriers to an inclusive classroom that emerged from the interviews in four key areas: 1) Course structure and outcomes, 2) Building community and belonging, 3) Instructional strategies, 4)Instructor development related to diversity, equity, and inclusion

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina : A Rare Gynecological Tumor

Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in English-language journals is less than 30. Due to this extremely low incidence, no specific treatment guidelines have been established, and most of what is clinically known is derived from a handful of single case reports. However, as befitting its highly aggressive histologic features, which are reminiscent of small cell lung cancer (SCLC), first-line treatment is modeled after SCLC. Herein is reported the case of a 51-year-old African-American patient with metastatic biopsy-proven small cell carcinoma of the vagina that progressed through multiple therapies: first-line cisplatin and etoposide (making it platinum-resistant) and radiotherapy, followed by the tumor macrophage-stimulating agent RRx-001 in a clinical trial called QUADRUPLE THREAT, which per protocol preceded a mandated rechallenge with cisplatin and etoposide. RECIST v.1.1 tumor progression on both RRx-001 and cisplatin/etoposide was accompanied by central necrosis in several of the enlarged lymph nodes and hepatic metastases, which may have been evidence of pseudoprogression, accounting for her ongoing longer-than-expected survival, since the necrotic tissue may have primed the activity of the PD-1 inhibitor. The lack of response to RRx-001 is hypothesized to have correlated with sparse tumor macrophage infiltration, seen on pre-and post-treatment biopsies, since the mechanism of action of RRx-001 relates to stimulation of tumor-associated macrophages. (C) 2017 The Author(s) Published by S. Karger AG, BaselPeer reviewe